Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle. Tufts Center for the Study ...
To establish whether molecules other than scFv antibody fragments could be lipid-modified and inserted into cell membranes, we cloned the gene encoding human interleukin-2 (IL-2) into vector pLP2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback